RecruitingPhase 1NCT06469450

KF2023#1-Trial: Influence of Statin Intake on Cellular Readouts


Sponsor

Mikko Niemi

Enrollment

15 participants

Start Date

Apr 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

A majority of high-risk patients does not achieve their cholesterol target levels and most of these patients do not receive more effective combination therapy, which goes beyond statin monotherapy. Large interindividual differences in treatment outcomes have been observed for patients receiving statins. Statins block cholesterol synthesis and increase cellular low-density lipoprotein (LDL) uptake. Importantly, LDL uptake is highly divergent in individuals.The aim of this trial is to investigate how atorvastatin influences leukocyte readouts of LDL uptake and lipid storage in humans. The trial is a single-arm, open-label, interventional trial. A total of 15 healthy volunteers will receive 40 mg atorvastatin once a day for 4 weeks. The participants will provide blood samples before starting the atorvastatin intervention, each week when taking atorvastatin, and one week after the end of the intervention for the measurement of leukocyte readouts of LDL uptake and lipid storage.


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria5

  • a signed written informed consent
  • age 18-40 years
  • healthy, and
  • Accepted results from laboratory tests (blood haemoglobin, basic blood count and blood platelets, alanine aminotransferase, alkaline phosphatase, glutamyl transferase, creatinine, plasma potassium and sodium). Negative pregnancy test result (serum human chorionic gonadotropin) for women.
  • Fully vaccinated against COVID-19.

Exclusion Criteria12

  • significant disease
  • smoking
  • SLCO1B1 poor function genotype
  • oral contraception or other continuous medication
  • pregnancy, planning of pregnancy or breastfeeding
  • participating in a clinical trial less than 3 months ago
  • donating blood less than 3 months ago
  • marked obesity
  • anticipated difficulties in drawing blood samples
  • weight less than 45 kg
  • BMI less than 18.5 kg/m2 or
  • inadequate Finnish language skills

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtorvastatin

one 40 mg atorvastatin tablet once daily for 28 days


Locations(1)

Department of Clinical Pharmacology

Helsinki, Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06469450


Related Trials